Another article about Ramaswamy’s companies
https://www.fiercebiotech.com/biotech/why-axovant-s-315m-ipo-bonanza-should-scare-hell-out-of-you
The fact that someone can make something of this size out of virtually nothing should be of concern to everyone in the industry. Magical thinking will take you just so far (remember the intoxicating dot-com days?). The argument that the market for biotech can stay stable rests on the belief that many of these new technologies in the clinic offer a fundamentally new and better way to treat many diseases. Something real. But when biotech mania takes over and perfectly legal schemes like this rain money, the pitfalls start to look like the Grand Canyon.
It looks bad when you turn things on the side and squint really hard. After all, if the person is competative with ideas he has to be evil, amiright?